N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor – SYS-CON Media (press release) (blog)
N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor SYS-CON Media (press release) (blog) N6022 is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. The initial Phase 1 testing in healthy ... and more » |